|
1
|
GBD 2023 Breast Cancer Collaborators, .
Global, regional, and national burden of breast cancer among
females, 1990–2023, with forecasts to 2050: A systematic analysis
for the Global Burden of Disease Study 2023. Lancet Oncol.
27:302–326. 2026. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2017. CA Cancer J Clin. 67:7–30. 2017.PubMed/NCBI
|
|
3
|
Kaufmann M, von Minckwitz G, Bear HD,
Buzdar A, McGale P, Bonnefoi H, Colleoni M, Denkert C, Eiermann W,
Jackesz R, et al: Recommendations from an international expert
panel on the use of neoadjuvant (primary) systemic treatment of
operable breast cancer: New perspectives 2006. Ann Oncol.
18:1927–1934. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Morrow M, Jagsi R, Alderman AK, Griggs JJ,
Hawley ST, Hamilton AS, Graff JJ and Katz SJ: Surgeon
recommendations and receipt of mastectomy for treatment of breast
cancer. JAMA. 302:1551–1556. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gulis K, Ellbrant J, Svensjö T, Skarping
I, Vallon-Christersson J, Loman N, Bendahl PO and Rydén L: A
prospective cohort study identifying radiologic and tumor related
factors of importance for breast conserving surgery after
neoadjuvant chemotherapy. Eur J Surg Oncol. 49:1189–1195. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Buchholz TA, Mittendorf EA and Hunt KK:
Surgical considerations after neoadjuvant chemotherapy: Breast
conservation therapy. J Natl Cancer Inst Monogr. 2015:11–14. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Gralow JR, Burstein HJ, Wood W, Hortobagyi
GN, Gianni L, von Minckwitz G, Buzdar AU, Smith IE, Symmans WF,
Singh B, et al: Preoperative therapy in invasive breast cancer:
Pathologic assessment and systemic therapy issues in operable
disease. J Clin Oncol. 26:814–819. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Masuda N, Lee SJ, Ohtani S, Im YH, Lee ES,
Yokota I, Kuroi K, Im SA, Park BW, Kim SB, et al: Adjuvant
capecitabine for breast cancer after preoperative chemotherapy. N
Engl J Med. 376:2147–2159. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Spring LM, Fell G, Arfe A, Sharma C,
Greenup R, Reynolds KL, Smith BL, Alexander B, Moy B, Isakoff SJ,
et al: Pathologic complete response after neoadjuvant chemotherapy
and impact on breast cancer recurrence and survival: A
comprehensive Meta-analysis. Clin Cancer Res. 26:2838–2848. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Krishnan Y, Alawadhi SA, P SS, Gopal M and
Thuruthel S: Pathological responses and long-term outcome analysis
after neoadjuvant chemotheraphy in breast cancer patients from
Kuwait over a period of 15 years. Ann Saudi Med. 33:443–450. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Rouzier R, Perou CM, Symmans WF, Ibrahim
N, Cristofanilli M, Anderson K, Hess KR, Stec J, Ayers M, Wagner P,
et al: Breast cancer molecular subtypes respond differently to
preoperative chemotherapy. Clin Cancer Res. 11:5678–5685. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Gorzelak-Magiera A, Kabut J, Sadurska J,
Długaszek A, Domagała-Haduch M, Szot A and Gisterek-Grocholska I:
Pathological complete response after neoadjuvant chemotherapy in
breast cancer: A literature overview. Cancers (Basel). 18:17182026.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hashmi AA, Bukhari U, Najam J, Dowlah T,
Ali AH, Diwan MA, Anjali F, Sham S, Zia S and Irfan M: Luminal B,
human epidermal growth factor receptor 2 (HER2/neu), and
Triple-Negative breast cancers associated with a better
chemotherapy response than luminal A breast cancers in
postneoadjuvant settings. Cureus. 15:e400662023.PubMed/NCBI
|
|
14
|
Dialani V, Chadashvili T and Slanetz PJ:
Role of imaging in neoadjuvant therapy for breast cancer. Ann Surg
Oncol. 22:1416–1424. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Schott AF and Hayes DF: Defining the
benefits of neoadjuvant chemotherapy for breast cancer. J Clin
Oncol. 30:1747–1749. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wang H and Mao X: Evaluation of the
efficacy of neoadjuvant chemotherapy for breast cancer. Drug Des
Devel Ther. 14:2423–2433. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Huang Z, Chen L, Wang Y, Fu L and Lv R:
Molecular markers, pathology, and ultrasound features of invasive
breast cancer. Clin Imaging. 79:85–93. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhang H, Wang L, Lin Y, Ha X, Huang C and
Han C: Classification of molecular subtypes of breast cancer using
radiomic features of preoperative ultrasound images. J Imaging
Inform Med. 38:2865–2877. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Marinovich ML, Houssami N, Macaskill P,
von Minckwitz G, Blohmer JU and Irwig L: Accuracy of ultrasound for
predicting pathologic response during neoadjuvant therapy for
breast cancer. Int J Cancer. 136:2730–2737. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Harbeck N: Neoadjuvant and adjuvant
treatment of patients with HER2-positive early breast cancer.
Breast. 62 (Suppl 1):S12–S16. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chen Y, Qi Y and Wang K: Neoadjuvant
chemotherapy for breast cancer: An evaluation of its efficacy and
research progress. Front Oncol. 13:11690102023. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Okano M, Oshi M, Butash AL, Asaoka M,
Katsuta E, Peng X, Qi Q, Yan L and Takabe K: Estrogen receptor
positive breast cancer with high expression of androgen receptor
has less cytolytic activity and worse response to neoadjuvant
chemotherapy but better survival. Int J Mol Sci. 20:26552019.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Schettini F and Prat A: Dissecting the
biological heterogeneity of HER2-positive breast cancer. Breast.
59:339–350. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Luen SJ, Salgado R, Dieci MV, Vingiani A,
Curigliano G, Gould RE, Castaneda C, D'Alfonso T, Sanchez J, Cheng
E, et al: Prognostic implications of residual disease
tumor-infiltrating lymphocytes and residual cancer burden in
triple-negative breast cancer patients after neoadjuvant
chemotherapy. Ann Oncol. 30:236–242. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Li X, Liu J, Wang Z, Li X, Feng K, Zhang
R, He J and Zhang H: Prediction model incorporating dynamic changes
in serum tumor markers for evaluating the efficacy of neoadjuvant
chemotherapy in patients with breast cancer: A retrospective cohort
study. Eur J Med Res. 30:12352025. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Manginstar C, Oley MH, Oley MC, Merung M,
Langi F, Kepel BJ, Rusli LV, Islam AA and Faruk M: Correlation
analysis of HIF-1α and Ca15-3 in response to neoadjuvant
chemotherapy in locally advanced breast cancer: A cohort study in
Indonesia. Breast Dis. 41:481–487. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
He L, Zhang W, Huang L, Lin X and Huang W:
A retrospective analysis of a serum multi-biomarker (CA153, TSGF,
and CYFRA 21-1) logistic regression model for predicting pathologic
complete response to neoadjuvant chemotherapy in breast cancer.
Breast Cancer (Dove Med Press). 18:5673012026.PubMed/NCBI
|
|
28
|
Eniseler EB, Çetin B, Ekinci F, Erdoğan AP
and Şahbazlar M: Exploratory evaluation of CA 15-3 × NLR score for
predicting pathologic complete response in breast cancer patients
undergoing neoadjuvant chemotherapy. Clin Transl Oncol. 28:527–532.
2026. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Fujimoto Y, Higuchi T, Nishimukai A,
Miyagawa Y, Kira A, Ozawa H, Bun A, Imamura M and Miyoshi Y: High
levels of serum CA15-3 and residual invasive tumor size are
associated with poor prognosis for breast cancer patients with
non-pathological complete response after neoadjuvant chemotherapy.
J Surg Oncol. 118:228–237. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Baumgartner A, Tausch C, Hosch S,
Papassotiropoulos B, Varga Z, Rageth C and Baege A:
Ultrasound-based prediction of pathologic response to neoadjuvant
chemotherapy in breast cancer patients. Breast. 39:19–23. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Gradishar WJ, Anderson BO, Balassanian R,
Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A,
Giordano SH, et al: NCCN Guidelines insights: Breast cancer,
version 1.2017. J Natl Compr Canc Netw. 15:433–451. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Hou W, Yao Q, Niu DF and Xue WC:
Clinicopathological characteristics related to Miller/Payne grading
system of breast carcinoma after neoadjuvant therapy and
establishment of novel prediction models. Zhonghua Bing Li Xue Za
Zhi. 51:743–748. 2022.(In Chinese). PubMed/NCBI
|
|
33
|
Coates AS, Winer EP, Goldhirsch A, Gelber
RD, Gnant M, Piccart-Gebhart M, Thürlimann B and Senn HJ: Tailoring
therapies-improving the management of early breast cancer: St
Gallen international expert consensus on the primary therapy of
early breast cancer 2015. Ann Oncol. 26:1533–1546. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Thürlimann B: St. Gallen international
breast cancer conferences & Consensus. Transl Breast Cancer
Res. 5:222024. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Jiang Z, Li J, Chen J, Liu Y, Wang K, Nie
J, Wang X, Hao C, Yin Y, Wang S, et al: Chinese society of clinical
oncology (CSCO) Breast cancer guidelines 2022. Transl Breast Cancer
Res. 3:132022. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Shen B, Wang K and Jiang Z: Updated
interpretation for early breast cancer in The Chinese Society of
Clinical Oncology Breast Cancer (CSCO BC) guidelines. TBCR.
2:20212021.
|
|
37
|
Giuliano AE, Edge SB and Hortobagyi GN:
Eighth edition of the AJCC cancer staging manual: Breast cancer.
Ann Surg Oncol. 25:1783–1785. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Kim R, Chang JM, Lee HB, Lee SH, Kim SY,
Kim ES, Cho N and Moon WK: Predicting axillary response to
neoadjuvant chemotherapy: Breast MRI and US in patients with
Node-positive breast cancer. Radiology. 293:49–57. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Hosmer DW, Hosmer T, Le Cessie S and
Lemeshow S: A comparison of goodness-of-fit tests for the logistic
regression model. Stat Med. 16:965–980. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Ring A, Webb A, Ashley S, Allum WH, Ebbs
S, Gui G, Sacks NP, Walsh G and Smith IE: Is surgery necessary
after complete clinical remission following neoadjuvant
chemotherapy for early breast cancer? J Clin Oncol. 21:4540–4545.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Cortazar P, Zhang L, Untch M, Mehta K,
Costantino JP, Wolmark N, Bonnefoi H, Cameron D, Gianni L,
Valagussa P, et al: Pathological complete response and long-term
clinical benefit in breast cancer: The CTNeoBC pooled analysis.
Lancet. 384:164–172. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Fisher B, Bryant J, Wolmark N, Mamounas E,
Brown A, Fisher ER, Wickerham DL, Begovic M, DeCillis A, Robidoux
A, et al: Effect of preoperative chemotherapy on the outcome of
women with operable breast cancer. J Clin Oncol. 16:2672–2685.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Bonadonna G, Valagussa P, Brambilla C,
Ferrari L, Moliterni A, Terenziani M and Zambetti M: Primary
chemotherapy in operable breast cancer: Eight-year experience at
the Milan Cancer Institute. J Clin Oncol. 16:93–100. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Štorkánová H, Oreská S, Špiritović M,
Heřmánková B, Bubová K, Komarc M, Pavelka K, Vencovský J, Distler
JHW, Šenolt L, et al: Plasma Hsp90 levels in patients with systemic
sclerosis and relation to lung and skin involvement: A
cross-sectional and longitudinal study. Sci Rep. 11:12021.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Liu Y, Wang Y, Wang Y, Xie Y, Cui Y, Feng
S, Yao M, Qiu B, Shen W, Chen D, et al: Early prediction of
treatment response to neoadjuvant chemotherapy based on
longitudinal ultrasound images of HER2-positive breast cancer
patients by Siamese multi-task network: A multicentre,
retrospective cohort study. EClinicalMedicine. 52:1015622022.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Wang X, Zhang Y, Yang M, Wu N, Wang S,
Chen H, Zhou T, Zhang Y, Wang X, Jin Z, et al: Dynamic
ultrasound-based modeling predictive of response to neoadjuvant
chemotherapy in patients with early breast cancer. Sci Rep.
14:316442024. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Zuo Y, Zhan Y, Zhou J, Xia H, Li T, Zhou
F, Luo C, Zeng H and Li Y: Prediction of pathological complete
response to neoadjuvant chemotherapy for invasive breast cancers
based on longitudinal ultrasound and superb microvascular imaging:
A single-center retrospective study. PeerJ. 13:e201712025.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Dobruch-Sobczak KS,
Piotrzkowska-Wróblewska H, Karwat P, Klimonda Z,
Markiewicz-Grodzicka E and Litniewski J: Quantitative assessment of
the echogenicity of a breast tumor predicts the response to
neoadjuvant chemotherapy. Cancers (Basel). 13:35462021. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Xu Y, Zhang W, Wang S, Xu L, Xu H, Chen R,
Shi X, Huang X, Wang Y, He J, et al: Volume change rate before and
after neoadjuvant systemic therapy of breast cancer is an
efficacious evaluation index to predict pathological complete
response. Front Oncol. 13:9108692023. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Wojcinski S, Soliman AA, Schmidt J,
Makowski L, Degenhardt F and Hillemanns P: Sonographic features of
triple-negative and non-triple-negative breast cancer. J Ultrasound
Med. 31:1531–1541. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Dent R, Trudeau M, Pritchard KI, Hanna WM,
Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P and Narod SA:
Triple-negative breast cancer: Clinical features and patterns of
recurrence. Clin Cancer Res. 13:4429–4434. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Kim SY, Cho N, Choi Y, Lee SH, Ha SM, Kim
ES, Chang JM and Moon WK: Factors affecting pathologic complete
response following neoadjuvant chemotherapy in breast cancer:
Development and validation of a predictive nomogram. Radiology.
299:290–300. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Adrada BE, Candelaria R, Moulder S,
Thompson A, Wei P, Whitman GJ, Valero V, Litton JK, Santiago L,
Scoggins ME, et al: Early ultrasound evaluation identifies
excellent responders to neoadjuvant systemic therapy among patients
with triple-negative breast cancer. Cancer. 127:2880–2887. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Ochi T, Tsunoda H, Matsuda N, Nozaki F,
Suzuki K, Takei H and Yamauchi H: Accuracy of morphologic change
measurements by ultrasound in predicting pathological response to
neoadjuvant chemotherapy in triple-negative and HER2-positive
breast cancer. Breast Cancer. 28:838–847. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Sabeti S, Larson NB, Boughey JC, Stan DL,
Solanki MH, Fazzio RT, Fatemi M and Alizad A: Ultrasound-based
quantitative microvasculature imaging for early prediction of
response to neoadjuvant chemotherapy in patients with breast
cancer. Breast Cancer Res. 27:242025. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Guo J, Wang BH, He M, Fu P, Yao M and
Jiang T: Contrast-enhanced ultrasonography for early prediction of
response of neoadjuvant chemotherapy in breast cancer. Front Oncol.
12:10266472022. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Shia WC, Chen DR, Huang YL, Wu HK and Kuo
SJ: Effectiveness of evaluating tumor vascularization using 3D
power Doppler ultrasound with high-definition flow technology in
the prediction of the response to neoadjuvant chemotherapy for T2
breast cancer: A preliminary report. Phys Med Biol. 60:7763–7778.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Zhang L, Bao LY, Tan YJ, Zhu LQ, Xu XJ,
Zhu QQ, Shan YN, Zhao J, Xie LS and Liu J: Diagnostic performance
using automated breast ultrasound system for breast cancer in
chinese women aged 40 Years or older: A comparative study.
Ultrasound Med Biol. 45:3137–3144. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Kim MJ, Eun NL, Ahn SG, Kim JH, Youk JH,
Son EJ, Jeong J, Cha YJ and Bae SJ: Elasticity values as a
predictive modality for response to neoadjuvant chemotherapy in
breast cancer. Cancers (Basel). 16:3772024. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Luo J, Lin Y, Zeng Z, Deng H and Li T:
Research of ultrasonic shear wave elastography in evaluating the
efficiency of neoadjuvant chemotherapy for breast cancer. J Clin
Ultrasound. 53:1026–1034. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Gu JH, He C, Zhao QY and Jiang TA:
Usefulness of new shear wave elastography in early predicting the
efficacy of neoadjuvant chemotherapy for patients with breast
cancer: Where and when to measure is optimal? Breast Cancer.
29:478–486. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Sigrist RMS, Liau J, Kaffas AE, Chammas MC
and Willmann JK: Ultrasound Elastography: Review of techniques and
clinical applications. Theranostics. 7:1303–1329. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Emanuelle Pereira Santos V, Luiz de França
Neto P, Eda de Oliveira Isídio B, Henrique Bezerra Fontes P,
Andrêssa de Moura I, Isabel Santos Cruz B, Máyra Gois de Sousa M,
Luana Dos Santos D, de França São Marcos B, Sousa de Pinho S, et
al: An overview about biomarkers in breast cancer: Insights into
the diagnostic and prognostic significance. Clin Chim Acta.
567:1200302025. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Krystel-Whittemore M, Tan PH and Wen HY:
Predictive and prognostic biomarkers in breast tumours. Pathology.
56:186–191. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Iwamoto N, Aruga T, Horiguchi S, Saita C,
Onishi M, Goto R, Ishiba T, Honda Y, Miyamoto H and Kuroi K:
Predictive factors of an axillary pathological complete response of
node-positive breast cancer to neoadjuvant chemotherapy. Surg
Today. 50:178–184. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Jung YJ, Lee S, Kang SK, Kim JY, Choo KS,
Nam KJ, Joo JH, Kim JJ and Kim HY: Clinicopathological factors
predicting pathological complete response to neoadjuvant Anti-HER2
therapy in HER2-positive breast cancer. Oncology. 103:351–359.
2025.PubMed/NCBI
|
|
67
|
Ruibal A, Sánchez Salmón A, Garrido M,
Bogdan Ciobotaru A and Arias JI: Preoperative CA15.3 serum levels
and cellular proliferation in patients having infiltrating ductal
carcinomas of the breast. Rev Esp Med Nucl. 26:367–371. 2007.(In
Spanish). View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Nam SE, Lim W, Jeong J, Lee S, Choi J,
Park H, Jung YS, Jung SP and Bae SY: The prognostic significance of
preoperative tumor marker (CEA, CA15-3) elevation in breast cancer
patients: Data from the Korean Breast Cancer Society Registry.
Breast Cancer Res Treat. 177:669–678. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Bao H, Yu D, Wang J, Qiu T, Yang J and
Wang L: Predictive value of serum anti-p53 antibodies,
carcino-embryonic antigen, carbohydrate antigen 15-3, estrogen
receptor, progesterone receptor and human epidermal growth factor
receptor-2 in taxane-based and anthracycline-based neoadjuvant
chemotherapy in locally advanced breast cancer patients. Anticancer
Drugs. 19:317–323. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Chen R, Ye Y, Yang C, Peng Y, Zong B, Qu
F, Tang Z, Wang Y, Su X, Li H, et al: Assessment of the predictive
role of pretreatment Ki-67 and Ki-67 changes in breast cancer
patients receiving neoadjuvant chemotherapy according to the
molecular classification: A retrospective study of 1010 patients.
Breast Cancer Res Treat. 170:35–43. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Miyashita M, Sasano H, Tamaki K, Chan M,
Hirakawa H, Suzuki A, Tada H, Watanabe G, Nemoto N, Nakagawa S, et
al: Tumor-infiltrating CD8+ and FOXP3+ lymphocytes in
triple-negative breast cancer: Its correlation with pathological
complete response to neoadjuvant chemotherapy. Breast Cancer Res
Treat. 148:525–534. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Guestini F, Ono K, Miyashita M, Ishida T,
Ohuchi N, Nakagawa S, Hirakawa H, Tamaki K, Ohi Y, Rai Y, et al:
Impact of topoisomerase IIα, PTEN, ABCC1/MRP1, and KI67 on
triple-negative breast cancer patients treated with neoadjuvant
chemotherapy. Breast Cancer Res Treat. 173:275–288. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Chen X, He C, Han D, Zhou M, Wang Q, Tian
J, Li L, Xu F, Zhou E and Yang K: The predictive value of Ki-67
before neoadjuvant chemotherapy for breast cancer: A systematic
review and meta-analysis. Future Oncol. 13:843–857. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Wong SH, Zhao L, Zhang X, Nakatsu G, Han
J, Xu W, Xiao X, Kwong TNY, Tsoi H, Wu WKK, et al: Gavage of fecal
samples from patients with colorectal cancer promotes intestinal
carcinogenesis in germ-free and conventional mice.
Gastroenterology. 153:1621–1633.e1626. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Falo C, Azcarate J, Fernandez-Gonzalez S,
Perez X, Petit A, Perez H, Vethencourt A, Vazquez S, Laplana M,
Ales M, et al: Breast cancer Patient's outcomes after neoadjuvant
chemotherapy and surgery at 5 and 10 years for stage II–III
disease. Cancers (Basel). 16:24212024. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
von Minckwitz G, Huang CS, Mano MS, Loibl
S, Mamounas EP, Untch M, Wolmark N, Rastogi P, Schneeweiss A,
Redondo A, et al: Trastuzumab emtansine for residual invasive
HER2-positive breast cancer. N Engl J Med. 380:617–628. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Harbeck N, Penault-Llorca F, Cortes J,
Gnant M, Houssami N, Poortmans P, Ruddy K, Tsang J and Cardoso F:
Breast cancer. Nat Rev Dis Primers. 5:662019. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Feeney G, Waldron R, Miller N, Malone C,
Sweeney K, McLaughlin R, Lowery A, Barry K and Kerin M: Association
of clinical biomarkers and response to neoadjuvant therapy in
breast cancer. Irish J Med Sci. 193:605–613. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Houssami N, Macaskill P, von Minckwitz G,
Marinovich ML and Mamounas E: Meta-analysis of the association of
breast cancer subtype and pathologic complete response to
neoadjuvant chemotherapy. Eur J Cancer. 48:3342–3354. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Castro PJTD, Janela Jacinto J, Marta Nuñez
HM, Cunha RCNB, Ladeira KM and Sousa M: 329eP Predictors of
pathological complete response following neoadjuvant chemotherapy
in breast cancer: A real-world analysis. ESMO Open. 11:1072802026.
View Article : Google Scholar
|
|
81
|
Liedtke C, Mazouni C, Hess KR, André F,
Tordai A, Mejia JA, Symmans WF, Gonzalez-Angulo AM, Hennessy B,
Green M, et al: Response to neoadjuvant therapy and long-term
survival in patients with triple-negative breast cancer. J Clin
Oncol. 26:1275–1281. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Liu YS, Li ZJ, Wang H and Zhou JQ:
Clinical value of ultrasound combined with the nutritional risk
index in predicting the efficacy of neoadjuvant chemotherapy for
breast cancer: An observational study. Medicine (Baltimore).
105:e470702026. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Gu J, Tong T, He C, Xu M, Yang X, Tian J,
Jiang T and Wang K: Deep learning radiomics of ultrasonography can
predict response to neoadjuvant chemotherapy in breast cancer at an
early stage of treatment: A prospective study. Eur Radiol.
32:2099–2109. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Jiang C, Zhang X, Qu T, Yang X, Xiu Y, Yu
X, Zhang S, Qiao K, Meng H, Li X, et al: The prediction of pCR and
chemosensitivity for breast cancer patients using DLG3, RADL and
Pathomics signatures based on machine learning and deep learning.
Transl Oncol. 46:1019852024. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Wu L, Ye W, Liu Y, Chen D, Wang Y, Cui Y,
Li Z, Li P, Li Z, Liu Z, et al: An integrated deep learning model
for the prediction of pathological complete response to neoadjuvant
chemotherapy with serial ultrasonography in breast cancer patients:
A multicentre, retrospective study. Breast Cancer Res. 24:812022.
View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Jiang M, Li CL, Luo XM, Chuan ZR, Lv WZ,
Li X, Cui XW and Dietrich CF: Ultrasound-based deep learning
radiomics in the assessment of pathological complete response to
neoadjuvant chemotherapy in locally advanced breast cancer. Eur J
Cancer. 147:95–105. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Liberman L and Menell JH: Breast imaging
reporting and data system (BI-RADS). Radiol Clin North Am.
40409–430. (v)2002. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Yan Y, Jiang T, Sui L, Ou D, Qu Y, Chen C,
Lai M, Ni C, Liu Y, Wang Y, et al: Combined conventional
ultrasonography with clinicopathological features to predict
axillary status after neoadjuvant therapy for breast cancer: A
case-control study. Bri J Radiol. 96:202303702023. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Zheng Q, Yan H, He Y, Wang J, Zhang N, Huo
L, Liu Y, Wang L, Xu L and Fan Z: An ultrasound-based nomogram for
predicting axillary node pathologic complete response after
neoadjuvant chemotherapy in breast cancer: Modeling and external
validation. Cancer. 130:1513–1523. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Li Z, Tong Y, Chen X and Shen K: Accuracy
of ultrasonographic changes during neoadjuvant chemotherapy to
predict axillary lymph node response in clinical node-positive
breast cancer patients. Front Oncol. 12:8458232022. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Bahrin NWS, Matusin SNI, Mustapa A, Huat
LZ, Perera S and Hamid M: Exploring the effectiveness of molecular
subtypes, biomarkers, and genetic variations as first-line
treatment predictors in Asian breast cancer patients: A systematic
review and meta-analysis. Syst Rev. 13:1002024. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Ding Y, Ding K, He X, Mo W, Liang C, Gong
L, Huang Y and Ding X: The value of neoadjuvant anthracycline-based
regimens for HER2-positive breast cancer: A systematic review and
meta-analysis including 1366 patients. Clin Med Insights Oncol.
17:117955492311952932023. View Article : Google Scholar : PubMed/NCBI
|
